As of May 31
| +0.335 / +0.71%|
The 18 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 44.36, with a high estimate of 56.34 and a low estimate of 38.68. The median estimate represents a -6.71% decrease from the last price of 47.56.
The current consensus among 18 polled investment analysts is to Hold stock in Novozymes A/S. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.